<DOC>
	<DOCNO>NCT02687594</DOCNO>
	<brief_summary>An oral highly potent P binder Velphoro mixture polynuclear iron ( III ) oxyhydroxide , sucrose , starch . It well tolerate clinical development program . The approved indication European Union ( EU ) control serums phosphorus ( sP ) level adult CKD ( Chronic kidney disease ) patient HD ( Haemodialysis ) PD ( Peritoneal dialysis ) . It major interest observe drug daily use outside control trial setting . The Marketing Authorisation Holder wish obtain systematic data within non-interventional study investigate short long-term safety . Effectiveness Treatment adherence real-life use evaluate .</brief_summary>
	<brief_title>Non-interventional Study Investigate Short Long Term Real-life Safety , Effectiveness , Adherence Velphoro® Patients With Hyperphosphataemia Undergoing Haemodialysis ( HD ) Peritoneal Dialysis ( PD )</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Age ≥18 year Signed informed consent Indication Velphoro treatment accordance SmPC Prevalent dialysis patient dialysis vintage least 6 month ( HD PD ) Treatmentnaïve pretreated antihyperphosphataemic therapy Prior participation NIS ( NonInterventional Study ) Parallel participation interventional study Enrolment prior clinical trial Velphoro</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>